| Completed | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge NCT03602079 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Completed | 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer NCT01939275 | City of Hope Medical Center | N/A |
| Terminated | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection NCT01249443 | AIDS Malignancy Consortium | Phase 1 |
| Completed | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointe NCT01846520 | City of Hope Medical Center | N/A |
| Completed | Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esop NCT01612546 | City of Hope Medical Center | Phase 2 |
| Terminated | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Meta NCT01705340 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer NCT01231399 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer NCT01191684 | City of Hope Medical Center | Phase 1 |
| Terminated | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors NCT01233505 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients NCT01100801 | National University Hospital, Singapore | Phase 2 |
| Completed | Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastr NCT00982592 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophag NCT00991952 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | A Study of Oraxol® in Gastric Cancer Patients NCT01491217 | Hanmi Pharmaceutical Company Limited | Phase 1 / Phase 2 |
| Completed | Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Canc NCT00607594 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384 | National Cancer Institute (NCI) | Phase 1 |
| Completed | S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer NCT00103324 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer NCT00098527 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroe NCT00084604 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carc NCT00084617 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer NCT00068380 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer NCT00064259 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Sto NCT00061932 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors NCT00028535 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |